GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress – Three Positive Phase 3 Epidiolex clinical trials reported in 2016 – – NDA submission and
Growth Capitalist (https://growthcapitalist.com/2016/12/gw-pharma-ends-fy16-with-483mm-in-cash/)
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress – Three Positive Phase 3 Epidiolex clinical trials reported in 2016 – – NDA submission and